Comparative efficacy of combination bronchodilator therapies in COPD: a network meta-analysis

References

• WHO methods and data sources for global causes of death 2000–2011Global Health Estimates Technical Paper WHO/HIS/HSI/GHE/2013.3 Available from: http://www.who.int/healthinfo/statistics/GlobalCOD_method.pdfAccessed April 16, 2014
   Google Scholar
• CazzolaMNoschesePSalzilloADe GiglioCD’AmatoGMateraMGBronchodilator response to formoterol after regular tiotropium or to tiotropium after regular formoterol in COPD patientsRespir Med20059952452815823447
   PubMed Web of Science ®Google Scholar
• van NoordJAAumannJLJanssensEComparison of tiotropium once daily, formoterol twice daily and both combined once daily in patients with COPDEur Respir J20052621422216055868
   PubMed Web of Science ®Google Scholar
• van NoordJAAumannJLJanssensEEffects of tiotropium with and without formoterol on airflow obstruction and resting hyperinflation in patients with COPDChest200612950951716537846
   PubMed Web of Science ®Google Scholar
• CelliBCraterGKilbrideSOnce-daily umeclidinium/vilanterol 125/25 mcg in COPD: a randomized, controlled studyChest Epub201411
   Web of Science ®Google Scholar
• DonohueJFMaleki-YazdiMRKilbrideSMehtaRKalbergCChurchAEfficacy and safety of once-daily umeclidinium/vilanterol 62.5/25 mcg in COPDRespir Med20131071538154623830094
   PubMed Web of Science ®Google Scholar
• FeldmanGWalkerRRBrooksJMehtaRCraterG28-day safety and tolerability of umeclidinium in combination with vilanterol in COPD: a randomized placebo-controlled trialPulm Pharmacol Ther20122546547122955035
   PubMed Web of Science ®Google Scholar
• KelleherDLMehtaRSJean-FrancoisBMSafety, tolerability, pharmacodynamics and pharmacokinetics of umeclidinium and vilanterol alone and in combination: a randomized crossover trialPLoS One20127e5071623284643
   PubMed Web of Science ®Google Scholar
• DecramerMAnzuetoAKerwinEEfficacy and safety of umeclidinium plus vilanterol versus tiotropium, vilanterol, or umeclidinium monotherapies over 24 weeks in patients with chronic obstructive pulmonary disease: results from two multicentre, blinded, randomised controlled trialsLancet Respir Med2014247248624835833
   PubMed Web of Science ®Google Scholar
• ANORO ELLIPTA [prescribing information] Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/203975s000lbl.pdfAccessed April 16, 2014
   Google Scholar
• BatemanEDFergusonGTBarnesNDual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE studyEur Respir J2013421484149423722616
   PubMed Web of Science ®Google Scholar
• DahlRJadayelDAlagappanVKChenHBanerjiDEfficacy and safety of QVA149 compared to the concurrent administration of its monocomponents indacaterol and glycopyrronium: the BEACON studyInt J Chron Obstruct Pulmon Dis2013850150824159259
   PubMed Web of Science ®Google Scholar
• DahlRChapmanKRRudolfMSafety and efficacy of dual bronchodilation with QVA149 in COPD patients: the ENLIGHTEN studyRespir Med20131071558156723867808
   PubMed Web of Science ®Google Scholar
• MahlerDADecramerMD’UrzoADual bronchodilation with QVA149 reduces patient-reported dyspnoea in COPD: BLAZE studyEur Respir J20134361599160924176997
   PubMed Web of Science ®Google Scholar
• VogelmeierCFBatemanEDPallanteJEfficacy and safety of once-daily QVA149 compared with twice-daily salmeterol-fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group studyLancet Respir Med20131516024321804
   PubMed Web of Science ®Google Scholar
• WedzichaJADecramerMFickerJHAnalysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group studyLancet Respir Med2013119920924429126
   PubMed Web of Science ®Google Scholar
• MahlerDAD’UrzoABatemanEDConcurrent use of indacaterol plus tiotropium in patients with COPD provides superior bronchodilation compared with tiotropium alone: a randomised, double-blind comparisonThorax20126778178822544891
   PubMed Web of Science ®Google Scholar
• TashkinDPPearleJIezzoniDVargheseSTFormoterol and tiotropium compared with tiotropium alone for treatment of COPDCOPD20096172519229704
   PubMedGoogle Scholar
• VogelmeierCKardosPHarariSGansSJStengleinSThirlwellJFormoterol mono- and combination therapy with tiotropium in patients with COPD: a 6-month studyRespir Med20081021511152018804362
   PubMed Web of Science ®Google Scholar
• AaronSDVandemheenKLFergussonDCanadian Thoracic Society/Canadian Respiratory Clinical Research ConsortiumTiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trialAnn Intern Med200714654555517310045
   PubMed Web of Science ®Google Scholar
• CazzolaMAndòFSantusPA pilot study to assess the effects of combining fluticasone propionate/salmeterol and tiotropium on the airflow obstruction of patients with severe-to-very severe COPDPulm Pharmacol Ther20072055656116914336
   PubMed Web of Science ®Google Scholar
• Ultibro Breezhaler (QVA149) approved in Europe2013 Available from: http://www.vectura.com/media/press-releases/2013/23-sep-2013.aspxAccessed April 16, 2014
   Google Scholar
• U.S. Food and Drug Administration (FDA)FDA news release. FDA approves Anoro Ellipta to treat chronic obstructive pulmonary disease2013 Available from: http://www.fda.gov/newsevents/newsroom/pres-sannouncements/ucm379057.htm2013Accessed April 16, 2014
   Google Scholar
• Dossier zur Nutzenbewertung gemäß § 35a SGB VIQWiGDokumentvorlage, Version vom 18.04.2013 Available from: https://www.g-ba.de/downloads/17-98-3528/2013-04-18_Anl2_6_Modul4.pdfAccessed April 16, 2014
   Google Scholar
• JansenJPNaciHIs network meta-analysis as valid as standard pairwise meta-analysis? It all depends on the distribution of effect modifiersBMC Med20131115923826681
   PubMed Web of Science ®Google Scholar
• CopeSZhangJSaletanSSmiechowskiBJansenJPSchmidPA process for assessing the feasibility of a network meta-analysis: a case study of everolimus in combination with hormonal therapy versus chemotherapy for advanced breast cancerBMC Med2014129324898705
   PubMed Web of Science ®Google Scholar
• DiasSSuttonAJAdesAEWeltonNJEvidence synthesis for decision making 2: a generalized linear modeling framework for pairwise and network meta-analysis of randomized controlled trialsMed Decis Making20133360761723104435
   PubMed Web of Science ®Google Scholar
• Maleki-YazdiMRKaelinTRichardNZvarichMChurchAEfficacy and safety of umeclidinium/vilanterol 62.5/25 mcg and tiotropium 18 mcg in chronic obstructive pulmonary disease: results of a 24-week, randomized, controlled trialRespir Med20141081752176025458157
   PubMed Web of Science ®Google Scholar
• DonohueJFvan NoordJABatemanEDA 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterolChest2002122475512114338
   PubMed Web of Science ®Google Scholar
• HuismanECockleSPunekarYComparative assessment of umeclidinium/vilanterol (UMEC/VI) combination therapy among symptomatic COPD patientsERJ20144458894
   Google Scholar
• KewKMDiasSCatesCJLong-acting inhaled therapy (beta-agonists, anticholinergics and steroids) for COPD: a network meta-analysisCochrane Database Syst Rev20143CD01084424671923
   PubMed Web of Science ®Google Scholar
• CopeSDonohueJFJansenJPComparative efficacy of long-acting bronchodilators for COPD – a network meta-analysisRespir Res20131410024093477
   PubMed Web of Science ®Google Scholar
• RajnoveanuRMAntoniuSUlmeanuRCombined long-acting bronchodilator single therapy for COPDExpert Opin Pharmacother20141513914224283778
   PubMed Web of Science ®Google Scholar
• TashkinDPFergusonGTCombination bronchodilator therapy in the management of chronic obstructive pulmonary diseaseRespir Res2013144923651244
   PubMed Web of Science ®Google Scholar
• KarabisALindnerLMocarskiMHuismanEGreeningAComparative efficacy of aclidinium versus glycopyrronium and tiotropium, as maintenance treatment of moderate to severe COPD patients: a systematic review and network meta-analysisInt J Chron Obstruct Pulmon Dis2013840542324043936
   PubMed Web of Science ®Google Scholar
• ChanCKMaltaisFSigouinCHaddonJMFordGTA randomized controlled trial to assess the efficacy of tiotropium in Canadian patients with chronic obstructive pulmonary diseaseCan Respir J20071446547218060091
   PubMed Web of Science ®Google Scholar
• TonnelABPerezTGrosboisJMVerkindreCBravoMLBrunMEffect of tiotropium on health-related quality of life as a primary efficacy endpoint in COPDInt J Chron Obstruct Pulmon Dis2008330131018686739
   PubMedGoogle Scholar
• TashkinDPCelliBSennSUPLIFT Study InvestigatorsA 4-year trial of tiotropium in chronic obstructive pulmonary diseaseN Engl J Med20083591543155418836213
   PubMed Web of Science ®Google Scholar
• CelliBDecramerMKestenSLiuDMehraSTashkinDPMortality in the 4-year trial of tiotropium (UPLIFT) in patients with chronic obstructive pulmonary diseaseAm J Respir Crit Care Med200918094895519729663
   PubMed Web of Science ®Google Scholar
• NiewoehnerDERiceKCoteCPrevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily inhaled anticholinergic bronchodilator: a randomized trialAnn Intern Med200514331732616144890
   PubMed Web of Science ®Google Scholar
• BrusascoVHodderRMiravitllesMKorduckiLTowseLKestenSHealth outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPDThorax20035839940412728159
   PubMed Web of Science ®Google Scholar
• CasaburiRMahlerDAJonesPWA long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary diseaseEur Respir J20021921722411866001
   PubMed Web of Science ®Google Scholar
• DonohueJFFogartyCLötvallJInhance Study InvestigatorsOnce-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropiumAm J Respir Crit Care Med201018215516220463178
   PubMed Web of Science ®Google Scholar
• KerwinEHébertJGallagherNEfficacy and safety of NVA237 versus placebo and tiotropium in patients with COPD: the GLOW2 studyEur Respir J2012401106111423060624
   PubMed Web of Science ®Google Scholar
• VerkindreCBartFAguilaniuBThe effect of tiotropium on hyperinflation and exercise capacity in chronic obstructive pulmonary diseaseRespiration20067342042716484769
   PubMed Web of Science ®Google Scholar
• CasaburiRBriggsDDJrDonohueJFSerbyCWMenjogeSSWitekTJJrThe spirometric efficacy of once-daily dosing with tiotropium in stable COPD: a 13-week multicenter trial. The US Tiotropium Study GroupChest20001181294130211083677
   PubMed Web of Science ®Google Scholar
• CovelliHBhattacharyaSCassinoCConoscentiCKestenSAbsence of electrocardiographic findings and improved function with once-daily tiotropium in patients with chronic obstructive pulmonary diseasePharmacotherapy2005251708171816305289
   PubMed Web of Science ®Google Scholar
• GarciaRFA randomised, double-blind, placebo-controlled, 12 weeks trial to evaluate the effect of Tiotropium Inhalation Capsules on the magnitude of exercise, measured using an accelerometer, in patients with Chronic Obstructive Pulmonary Disease (COPD)Boehringer Ingelheim Trial Results 2007 Available from: http://trials.boehringer-ingelheim.com/content/dam/internet/opu/clinicaltrial/com_EN/results/205/205.269.pdfAccessed April 16, 2014
   Google Scholar
• MoitaJBárbaraCCardosoJTiotropium improves FEV1 in patients with COPD irrespective of smoking statusPulm Pharmacol Ther20082114615117693107
   PubMed Web of Science ®Google Scholar